111 Capital Purchases New Holdings in Zoetis Inc. (NYSE:ZTS)

111 Capital purchased a new stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 17,101 shares of the company's stock, valued at approximately $2,786,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in ZTS. JPMorgan Chase & Co. boosted its holdings in Zoetis by 10.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,916,539 shares of the company's stock valued at $569,834,000 after purchasing an additional 279,092 shares during the period. Brighton Jones LLC raised its position in shares of Zoetis by 180.4% during the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company's stock valued at $754,000 after buying an additional 2,978 shares during the last quarter. Exchange Traded Concepts LLC lifted its stake in shares of Zoetis by 351.7% in the fourth quarter. Exchange Traded Concepts LLC now owns 7,404 shares of the company's stock valued at $1,206,000 after buying an additional 5,765 shares during the period. Flagship Harbor Advisors LLC lifted its stake in shares of Zoetis by 13.1% in the fourth quarter. Flagship Harbor Advisors LLC now owns 5,634 shares of the company's stock valued at $918,000 after buying an additional 652 shares during the period. Finally, PFG Investments LLC grew its position in Zoetis by 3.7% during the fourth quarter. PFG Investments LLC now owns 3,265 shares of the company's stock worth $532,000 after buying an additional 115 shares in the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Price Performance

Zoetis stock traded up $1.57 during mid-day trading on Friday, hitting $168.71. 5,467,815 shares of the company were exchanged, compared to its average volume of 2,533,285. The company has a market capitalization of $75.11 billion, a PE ratio of 30.84, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. The business has a fifty day moving average of $156.65 and a 200 day moving average of $164.63. Zoetis Inc. has a 1-year low of $139.70 and a 1-year high of $200.33. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09.

Zoetis (NYSE:ZTS - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The business had revenue of $2.22 billion for the quarter, compared to analyst estimates of $2.20 billion. During the same quarter in the prior year, the firm earned $1.38 EPS. The firm's quarterly revenue was up 1.4% compared to the same quarter last year. As a group, sell-side analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Friday, July 18th will be issued a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.19%. The ex-dividend date is Friday, July 18th. Zoetis's payout ratio is 35.91%.

Insider Transactions at Zoetis

In related news, Director Willie M. Reed sold 1,210 shares of the stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the sale, the director now directly owns 11,245 shares in the company, valued at $1,868,244.30. This represents a 9.71% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Roxanne Lagano sold 326 shares of the firm's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $170.00, for a total value of $55,420.00. Following the sale, the executive vice president now directly owns 15,781 shares of the company's stock, valued at $2,682,770. This represents a 2.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.18% of the company's stock.

Wall Street Analysts Forecast Growth

ZTS has been the subject of several recent research reports. Stifel Nicolaus cut their price target on Zoetis from $180.00 to $165.00 and set a "buy" rating for the company in a report on Monday, April 14th. Barclays boosted their price objective on Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research report on Friday, February 14th. Piper Sandler raised their target price on Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a research report on Monday, May 12th. UBS Group decreased their price target on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 7th. Finally, Morgan Stanley dropped their price objective on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a research note on Friday, February 14th. One analyst has rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, Zoetis has an average rating of "Buy" and a consensus price target of $212.75.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.